INVESTORS & MEDIA
News Release
Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Key data include presentations on the effects of Praluent across several patient subsets such as diabetes, heterozygous familial hypercholesterolemia (HeFH), and atherosclerotic cardiovascular disease (ASCVD) and post-hoc analyses on the effect of Praluent on major cardiovascular events (MACE). Additionally, a safety update utilizing real-world data from the Praluent open-label extension trial will be presented.
Praluent is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), which is approved in approximately 40 countries worldwide, including the
1) MODERATED POSTER PRESENTATIONS
- The PCSK9 revolution: new insights into evaluation and treatment
- Alirocumab efficacy and safety in patients with hypercholesterolemia and with or without clinical atherosclerotic cardiovascular disease: Pooled analysis of 10 ODYSSEY randomized trials (Jones)
- Abstract #1133M-03
Friday, March 17 , 10:00 -10:10 a.m. ET
- Alirocumab treatment in a real world setting: Safety update from an open-label treatment extension to the ODYSSEY program for patients with heterozygous familial hypercholesterolemia (Guyton)
- Abstract #1133M-07
Friday, March 17 , 10:30 -10:40 a.m. ET
- Impact of statin intolerance rates on ezetimibe and/or PCSK9 inhibitor use for meeting low-density lipoprotein goals in a real-world cohort with atherosclerotic cardiovascular disease (Cannon)
- Abstract #1133M-13
Friday, March 17 , 11:15 -11:25 a.m. ET
- A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of alirocumab in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid-modifying therapy in
South Korea andTaiwan (Koh) - Abstract #1133M-15
Friday, March 17 , 11:30 -11:40 a.m. ET
- Alirocumab efficacy and safety in patients with hypercholesterolemia and with or without clinical atherosclerotic cardiovascular disease: Pooled analysis of 10 ODYSSEY randomized trials (Jones)
- The intersection of diabetes and atherosclerotic cardiovascular disease (ASCVD)
- Alirocumab safety in individuals with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials (Leiter)
- Abstract #1222M-07
Saturday, March 18 , 1:00 -1:10 p.m. ET
- Alirocumab safety in individuals with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials (Leiter)
2) POSTER PRESENTATIONS
- Advances in cholesterol measurement and management
- Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in individuals with type 2 diabetes on maximally tolerated statin therapy (Muller-Wieland)
- Abstract #1106-055
Friday, March 17 , 10:00 -10:45 a.m. ET
- Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in individuals with type 2 diabetes on maximally tolerated statin therapy (Muller-Wieland)
- Traditional and novel factors used to assess the risk of, and used for the treatment of, coronary artery disease (CAD)
- Lower on-treatment low-density lipoprotein cholesterol is associated with lower cardiovascular risk in very high risk patients with atherosclerotic cardiovascular disease: analyses from the ODYSSEY trials (Ray)
- Abstract # 1126-316
Friday, March 17 , 10:00 -10:45 a.m. ET
- Lower on-treatment low-density lipoprotein cholesterol is associated with lower cardiovascular risk in very high risk patients with atherosclerotic cardiovascular disease: analyses from the ODYSSEY trials (Ray)
- Advances in lipid management
- Alirocumab reduces major cardiovascular events in individuals with atherosclerotic cardiovascular disease: a post-hoc analysis of ODYSSEY LONG TERM (Robinson)
- Abstract #1203-305
Saturday, March 18 , 9:45 -10:30 a.m. ET
- Use of high-intensity statin therapy post-acute coronary syndrome in the ongoing ODYSSEY OUTCOMES trial of alirocumab, a proprotein convertase subtilisin/kexin type 9 monoclonal antibody, versus placebo: Interim baseline data (Goodman)
- Abstract #1203-307
Saturday, March 18 , 9:45 -10:30 a.m. ET
- Alirocumab reduces major cardiovascular events in individuals with atherosclerotic cardiovascular disease: a post-hoc analysis of ODYSSEY LONG TERM (Robinson)
- Cardiac arrest, diabetes, and other high risk features of patients with acute coronary syndrome (ACS)
- Lower on-treatment low-density lipoprotein cholesterol is associated with lower cardiovascular risk in women: Analyses from the ODYSSEY trials of alirocumab versus control (Vallejo-Vaz)
- Abstract #1204-331
Saturday, March 18 , 9:45 -10:30 a.m. ET
- Lower on-treatment low-density lipoprotein cholesterol is associated with lower cardiovascular risk in women: Analyses from the ODYSSEY trials of alirocumab versus control (Vallejo-Vaz)
Additional information on ACC.17 is available on the congress website.
About Praluent
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL cholesterol levels in the blood. Praluent is the only PCSK9 inhibitor available in two dosages with two levels of efficacy (75 mg and 150 mg), allowing physicians to select the dose based on a patient's LDL cholesterol lowering needs.
Praluent is approved in approximately 40 countries worldwide, including the
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
IMPORTANT SAFETY INFORMATION FOR THE
Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT.
Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.
Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.
PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.
The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the "Instructions for Use" that comes with Praluent.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-
Please click here for the full Prescribing Information
About
About
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although
Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Contacts
Media Relations
Tel: +1 (908) 981-8745
ashleigh.koss@sanofi.com
Contacts Regeneron:
Tel: + 1 (914) 847-3456
Mobile: +1 (914) 260-8788
arleen.goldenberg@regeneron.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-analyses-at-acc17-scientific-sessions-300418970.html
SOURCE
News Provided by Acquire Media